Bladder Cancer Clinical Trial
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Histologically confirmed, unresectable locally advanced or metastatic urothelial carcinoma.
Must have received prior treatment with an immune checkpoint inhibitor (CPI).
Subjects must have received prior treatment with platinum-containing chemotherapy.
Subjects must have had progression or recurrence of urothelial cancer.
Subjects must have measurable disease according to RECIST (Version 1.1).
Adequate bone marrow function.
Adequate renal function.
Adequate liver function.
Adequate Eastern Cooperative Oncology Group (ECOG) performance status.
Preexisting sensory or motor neuropathy Grade ≥2.
Presence of symptomatic or uncontrolled central nervous system (CNS) metastases.
Prior treatment with enfortumab vedotin or other monomethylauristatin (MMAE)-based antibody-drug conjugate (ADCs)
Prior treatment with any anti-CD47 or anti-signal regulatory protein-α (SIRPα) agent.
Known active keratitis or corneal ulcerations. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated.
History of uncontrolled diabetes mellitus within 3 months of the first dose of study drug.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
New Haven Connecticut, 06520, United States
Tampa Florida, 33612, United States
Chicago Illinois, 60637, United States
Boston Massachusetts, 02114, United States
New York New York, 10065, United States
Chapel Hill North Carolina, 27599, United States
Portland Oregon, 97239, United States
Germantown Tennessee, 38138, United States
Dallas Texas, 75390, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.